In subjects with insulin-dependent diabetes mellitus, microalbuminuria has been associated with increased triglyceride and lipoprotein (a) (Lp[a]) concentrations and increased blood pressure. However, few studies have examined whether this association is present in subjects with non-insulin-dependent diabetes mellitus (NIDDM). We measured lipids, lipoproteins, Lp(a), blood pressure, and albumin excretion in 234 subjects with NIDDM from the San Antonio Heart Study, a population-based study of diabetes and cardiovascular disease. Seventy-two subjects had microalbuminuria (2:30 mg/dl). These subjects had increased systolic and diastolic blood pressures and higher fasting glucose concentrations relative to subjects without microalbuminuria. However, there were no significant differences between subjects with and without microalbuminuria with respect to lipids, lipoproteins, Lp(a), self-reported myocardial infarction, obesity, or body fat distribution. Subjects With diabetic retinopathy had increased microalbuminuria. In multivariate analysis both glycemia and blood pressure continued to be significantly related to the presence of microalbuminuria. We conclude that NIDDM subjects with microalbuminuria have elevated blood pressure and more severe glycemia but do not have a significantly more atherogenic pattern of lipids, lipoproteins, or Lp(a) than subjects without microalbuminuria. 
M
icroalbuminuria predicts progression to renal disease in insulin-dependent diabetes mellitus (IDDM)'- 3 and mortality in non-insulindependent diabetes (NIDDM). 4 It has also been associated with increased blood pressure, 5 ' 6 increased very low density lipoprotein (VLDL) cholesterol, and decreased high density lipoprotein (HDL) cholesterol 7 in subjects with IDDM. We have previously shown that nondiabetic subjects with microalbuminuria have significantly higher blood pressure levels, triglyceride concentrations, insulin concentrations, and prevalence of hypertension than nondiabetic subjects without microalbuminuria. 8 In nondiabetic subjects and also in subjects with NIDDM, microalbuminuria is a predictor of coronary heart disease. 4 ' 9 Few data exist, however, on whether microalbuminuria is a marker for increased cardiovascular risk factors in NIDDM. Subjects with NIDDM and microalbuminuria had increased triglyceride and decreased HDL cholesterol levels in one cross-sectional study, 10 but no lipid, lipoprotein, or blood pressure abnormalities were observed at baseline in another. 11 In the latter study, however, persistent microalbuminuria predicted atherogenic changes in lipoproteins but not changes in blood pressure 5 years later. 11 Recently, a number of studies have suggested that lipoprotein (a) (Lp [a] ) is a strong independent predictor of coronary heart disease. 12 " 16 Moreover, several studies have indicated that microalbuminuria is associated with increased Lp(a) concentrations in subjects with IDDM. 17 -19 In IDDM subjects with renal failure the increased Lp(a) concentrations associated with microalbuminuria are potentially important, since the mortality in IDDM subjects with renal failure is 40-100 times higher than in nondiabetic subjects, whereas IDDM subjects without renal failure have only a twofold to fourfold excess risk of mortality compared with nondiabetic subjects.
20
' 21 However, no study has examined Lp(a) concentrations in subjects with NIDDM and microaJbuminuria.
In this report, we examine the relation of microalbuminuria to lipids, lipoproteins, Lp(a), blood pressure, and glucose and insulin concentrations in NIDDM subjects from the San Antonio Heart Study, a population-based study of diabetes and cardiovascular disease.
to October 1988. The sampling design has been previously described in detail for both phases. 22 ' 23 Briefly, households were randomly sampled from three socioeconomicalry distinct neighborhoods: low, medium, and high income. All 25-to 64-year-old men and nonpregnant women residing in the selected households were considered eligible to participate. A total of 2,217 Mexican Americans and non-Hispanic whites were examined in phase 1 of the study and 2,957 Mexican Americans and non-Hispanic whites in phase 2. The overall response rate for both phases was 65.3%.
Mexican Americans were defined as individuals whose ancestry derived from a Mexican national origin. 24 Anthropometric measurements (height, weight, waist and hip circumferences, and subscapular and triceps skinfolds) were made after each participant had removed his or her shoes and upper garments. 25 Body mass index was calculated as weight (in kilograms) divided by height (in meters) squared. The ratio of waist-to-hip circumference (WHR) was chosen as a measure of upper body adiposity, and the ratio of subscapular-to-triceps skinfold (centrality) was chosen as a measure of central adiposity. A glucose tolerance test was performed in the morning on each participant with a 75-g glucose equivalent load (Koladex or Orangedex, Custom Laboratories, Baltimore, Md.). Individuals were instructed to fast for 12-14 hours before the test. After obtaining a fasting blood specimen, additional specimens were drawn 1 and 2 hours after administration of the glucose load. Plasma glucose concentrations were measured with an Abbott Bichromatic Analyzer (South Pasadena, Calif.). Serum insulin concentrations were measured with a commercial coated-tube radioimmunoassay. 23 Lipid and lipoprotein methods have been described previously. 22 Lp(a) was measured using a monoclonal anti-Lp(a) antibody (Terumo Medical Corp., Elkton, Md.). 26 The intra-assay coefficient of variation was 4%, and the interassay coefficient of variation was 8%. 26 Diabetes was diagnosed according to the plasma glucose criteria of the National Diabetes Data Group (fasting plasma glucose >140 mg/dl and/or both 1-and 2-hour postload plasma glucose >200 mg/dl). 27 Individuals who did not meet these criteria were also considered to be diabetic if they were currently taking either oral antidiabetic agents or insulin.
From 1984 to 1988, a diabetes complications examination was performed to assess the risk of diabetic retinopathy 28 and diabetic proteinuria. 29 Four hundred twenty-two diabetic subjects from both the phase 1 and phase 2 surveys were reexamined at this time. The response rate to the diabetes complications exam was 85%. Two hundred seventy-nine subjects were reexamined in 1990-1991 and form the basis of this report. The response rate to the 1990-1991 examination was 64%. Systolic (first phase) and diastolic (fifth phase) blood pressures were measured with a random-zero sphygmomanometer (Hawksley-Gelman, Sussex, England) on the right arm of the seated participant after at least a 5-minute rest. Three readings were obtained on each subject, and the average of the second and third reading was defined as the patient's blood pressure. 30 Hypertension was defined according to the Hypertension Detection and Follow-up Program criteria (diastolic blood pressure ^95 mm Hg and/or currently taking antihypertensive medications). 30 History of myocardial infarction, cigarette smoking, and treatment with lipid-lowering medicines were ascertained by self-report. Retinopathy was assessed by seven stereo retinal photographs using procedures adapted from the Early Treatment of Diabetic Retinopathy Study. 31 These methods have been previously described. 28 Photographs were read at the University of Wisconsin reading center by a modification 32 of the modified Airlie House classification.
3334
Retinopathy level 0 was coded as no retinopathy; levels 15-30, as background; levels 40-50, as preproliferative; and levels 60-80, as proliferative. 33 Urine specimens were not obtained from nine of the diabetic subjects who attended the 1990-1991 follow-up examination, leaving 270 subjects available for analysis. Both clinical proteinuria and microalbuminuria were assessed in an early morning spot urine specimen. Clinical proteinuria was measured by Albustix (Ames, Elkhart, Ind.). Thirty-six diabetic subjects had 1+ or greater proteinuria and were excluded from this report, leaving 234 subjects who were free of clinical proteinuria. After determination of clinical proteinuria, urine specimens were stored at -70°C. Microalbuminuria was determined an average of 9 months later by a quantitative immunoturbidimetric method (Ames, Slough, England). 35 - 36 The interassay coefficient of variation was 10%, and the intra-assay coefficient of variation was 7%. Previous studies have indicated that an early morning spot urine gives a good estimate of the 24-hour urinary excretion of albumin. 37 - 38 Elevated albumin excretion (e.g., microalbuminuria) was defined to be &30 mg/dl. 4 Analyses of variance were used with the presence or absence of microalbuminuria as the grouping variable ( Table 1 ). The dependent variables were lipids, lipoproteins, Lp(a), blood pressure, and glucose and insulin concentrations. For hypertension prevalence and the proportion of subjects with Lp(a) ^30 mg/dl (the threshold at which increased risk of coronary heart disease is thought to occur), a x 2 test was used to evaluate the association with microalbuminuria. Statistical analyses were performed using the SYSTAT statistical software. 39 Spearman correlations were used to assess the association between albumin excretion as a continuous variable and other variables ( Table 2) . Logistic regression analyses were performed using the program developed by Dallal 40 (Table 3 ). Table 1 shows the clinical characteristics of subjects with and without microalbuminuria. Subjects with microalbuminuria had significantly higher fasting glucose and systolic and diastolic blood pressures than subjects without microalbuminuria. There were no significant differences in age, ethnicity, triglyceride concentrations, cigarette smoking, self-reported myocardial infarction, proportion of subjects on lipid-lowering medications, obesity, body fat distribution, fasting insulin, total, low density lipoprotein (LDL), and HDL cholesterol, Lp(a), or prevalence of hypertension between diabetic subjects with and without microalbuminuria. There was a significant trend toward more severe retinopathy in subjects with microalbuminuria, and these subjects were more likely to be under treatment with insulin. Table 2 shows Spearman correlations between albumin excretion (treated as a continuous variable) and other variables. Albumin excretion was significantly related only to fasting glucose and systolic and diastolic blood pressures. Table 3 shows the relation of fasting glucose, systolic blood pressure, age, ethnicity, duration of diabetes, type of diabetic therapy, and obesity to the presence of microalbuminuria by multiple logistic regression analysis. We fit two different models. Model 1 includes fasting glucose and systolic blood pressure, which are well-recognized risk factors for microalbuminuria. Model 2 includes possible confounding variables, including obesity, body fat distribution, ethnicity, type of therapy, smoking, and diabetes duration. Fasting glucose and systolic blood pressure continued to be significantly related to the presence of microalbuminuria in model 2. In addition, this model showed a significant increase of microalbuminuria in Mexican American diabetic subjects, an effect that was only of borderline significance in Table 1 . We repeated these analyses including both self-reported myocardial infarction and retinopathy (data not shown). The former was not significantly related to the presence of microalbuminuria, but the level of retinopathy was.
Results

Discussion
We have shown in this report that microalbuminuria in subjects with NIDDM is not associated with an adverse pattern of lipids, lipoproteins, or Lp(a). These results are thus consistent with those of Niskanen et al, 11 who did not observe a relation between microalbuminuria and lipids and lipoproteins in subjects with NIDDM at baseline, although after 5 years of follow-up, subjects with microalbuminuria developed higher triglyceride and lower HDL cholesterol levels than subjects without microalbuminuria. In contrast, Mattock et al 10 did show a cross-sectional relation between lipids 42 and in normoglycemic subjects. 8 We also failed to observe any elevation in Lp(a) concentrations in NIDDM patients with microaibuminuria. This is the first report on microaibuminuria and Lp(a) concentrations in such patients. In contrast, Lp(a) concentrations have been reported to be elevated in IDDM subjects with microaibuminuria. 17 -19 The difference between the relation of microaibuminuria to Lp(a) in IDDM and NIDDM subjects is perhaps not surprising, since the effect of metabolic control on Lp(a) concentrations also appears to differ in IDDM and NIDDM. Lp(a) concentrations decrease with improved metabolic control in IDDM, 264344 but not in NIDDM. 45 ' 46 Both we 47 and others 46 have shown that NIDDM subjects do not have increased Lp(a) concentrations relative to nondiabetics. Subjects with renal failure, on the other hand, whether diabetic or nondiabetic, appear to have increased Lp(a) concentrations relative to subjects with normal renal function. 48 " 50 The present data indicate that NIDDM subjects with microaibuminuria have higher blood pressure and more severe glycemia. NIDDM patients with microaibuminuria are also more likely to be Mexican American. Table  3 indicates that the presence of microaibuminuria is independently related to both blood pressure and glycemia. These results are similar to the effect of microaibuminuria on these variables in IDDM.
56 - 51 In contrast, Niskanen et al n did not show an increase in blood pressure or hyperglycemia in NIDDM subjects with microaibuminuria. One limitation of the present report and most of the other reports in the literature is that in cross-sectional studies, one cannot determine causality. Thus, we cannot assess whether microaibuminuria causes an increase in blood pressure and glycemia or whether increased blood pressure and/or glycemia cause the development of microaibuminuria. Only prospective studies can resolve this issue. Another limitation of the present study is that we have only a single spot urine measurement for our subjects. Although analysis of early morning urine has been reported to give good estimates of 24-hour urine excretion rates, 37 -38 measurement of several samples might have improved the precision of the estimate of urine albumin. We also did not have urine creatinine determinations available to provide an estimate of 24-hour urinary excretion. Another possible explanation for the lack of association between microaibuminuria and cardiovascular risk factors is survival bias resulting from increased mortality among subjects with both microaibuminuria and increased risk factors. However, our population of diabetic subjects at the time of the 1990-1991 follow-up examination was still relatively young (50-52 years, Table 1 ), and thus mortality was relatively low. We have shown that the 8-year mortality of diabetic subjects is 14% (S.M. Haffner et al, unpublished observations).
In conclusion, we have shown that NIDDM patients with microalbuminuria have increased blood pressure and more severe glycemia. However, they do not have an adverse pattern of lipid, lipoprotein, or Lp(a) concentrations, unlike IDDM patients and normal subjects with microalbuminuria.
